Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.